Stockreport

INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials

INmune Bio Inc. - Common stock  (INMB) 
PDF Phase II program to focus on women with trastuzumab resistant HER2+ breast cancer LA JOLLA, Calif. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunology [Read more]